Brief: BerGenBio Receives FDA Fast Track Designation For Bemcentinib

Oncoinvent ASA

09/11/2021 13:14

Nov 9 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR
BEMCENTINIB
IN STK11-MUTATED ADVANCED/METASTATIC NON-SMALL LUNG
CANCER (NSCLC)
    * U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST
TRACK
DESIGNATION FOR BEMCENTINIB IN COMBINATION WITH AN ANTI-PD-(L)1
AGENT AS TREATMENT FOR PATIENTS WITH STK11 ALTERED
ADVANCED/METASTATIC NSCLC PATIENTS WITHOUT ACTIONABLE MUTATIONS.

Source text for Eikon:  ID:nWkr2SCTYX 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))